S-adenosylmethionine supplementation to alleviate depression symptoms in patients with suboptimal response to standard antidepressive therapy: a perspective.

Abstract

This review aims to determine the role of S-adenosylmethionine (SAMe) supplementation as an alternative therapeutic option, particularly for individuals with inadequate responses to conventional antidepressive treatments. The effects of SAMe on depression are analysed through its role in modulating neurotransmitter metabolism, reducing neuroinflammation, enhancing neuroplasticity, and regulating gene expression. These mechanisms may contribute to the efficacy of SAMe in treating depression, particularly in treatment-resistant cases. The review also addresses SAMe's potential use in managing other psychiatric disorders and neurological diseases.